Protein Structure Discovery Could Lead to Better Treatments for HIV, Early Aging

UVA Hospital

U.Va. Health System

Researchers at the University of Virginia School of Medicine have determined the molecular structure of a protein whose mutations have been linked to several early aging diseases, and to side effects of common HIV and AIDS medications. This breakthrough could eventually help researchers develop new treatments for these early aging diseases and redesign AIDS medications to avoid side effects, such as diabetes.

U.Va. Center for Membrane Biology researchers Peter S. Horanyi, Edward E. Pryor Jr., and Michael C. Wiener collaborated with groups from the Hauptman-Woodward Medical Research Institute and the University of Rochester School of Medicine and Dentistry to determine the molecular structure of the enzyme Ste24p. Their findings were published March 29 in the journal Science.

Their Membrane Protein Structural Biology Consortium is funded by the National Institutes of Health’s Protein Structure Initiative, which supports the determination of molecular structures of biomedically important target proteins.

The nucleus of a cell is lined with a mesh-like structure called lamin that serves as a scaffold for maintaining nuclear shape and function. Lamin requires the action of another protein, called Ste24p protease, which removes specific parts of the lamin filament and enables proper assembly of the mesh.

The research team determined the structure of a Ste24p protein found in a close relative of baker’s yeast, whose properties are interchangeable with the same protein found in humans.
The experiments required to solve the structure of Ste24p were performed remotely at the Advanced Photon Source, part of the Department of Energy’s Argonne National Laboratory near Chicago.

U.Va. funds access to the laboratory, Horanyi said, to enable researchers to use specialized X-ray crystallographic capabilities available through the South East Regional Collaborative Access Team at the Advanced Photon Source. Working from Charlottesville, U.Va. researchers can log onto a computer program to remotely control the robots to perform research and to collect data. “It’s like using a Web application,” Horanyi said.

In humans, improper processing and assembly of lamin leads to a group of diseases known as laminopathies, which include muscular dystrophy, cardiomyopathies and a collection of rare accelerated aging diseases in children called progerias. The research team focused on Ste24p, Pryor said, because defects in this protein in humans are responsible for a number of progerias.
In addition, some frequently used HIV and AIDS medications utilized in Highly Active Antiretroviral Therapy, or HAART, also interact with Ste24p, altering how patients taking the drugs metabolize fat and leading to treatment side effects that can include insulin resistance and diabetes, Pryor said.

Knowing how the protein is structured could aid researchers in developing drugs to treat progerias and could assist in the redesign of HAART medications to avoid the treatment side effects, Wiener said.

Pryor noted that Ste24p is a biomarker for normal aging in humans – as humans get older, this protein works less effectively. “So this mapping could provide insight to researchers into the aging process for humans,” he said.

Media Contact

Josh Barney

UVA Health